SQ2270 / Shasqi - LARVOL DELTA

SQ2270, a Novel MMAE-based Therapeutic, Promotes Tumor Growth Inhibition and Extensive Immune Cell Infiltration in the RENCA Cancer Model (SITC 2022) - P1/2 | "SQ3370, the lead asset, uses a Doxorubicin protodrug and is being evaluated in a Phase 1 clinical trial in solid tumors ( NCT04106492 ). (2) Protodrug, an attenuated therapy activated by click chemistry, is infused systemically. (3) Protodrug is captured by its click chemistry partner through a rapid covalent reaction between tetrazine and TCO moieties, followed by localized release of the active drug"

Preclinical • Oncology • Solid Tumor • CD8 • GZMB • PD-1 • PTPRC